• Vaccine Name: Brucella ovis Omp16 subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009126
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Sheep
• Host Species as Laboratory Animal Model: Mus musculus
• Antigen: Omp16; Omp19; Omp31; Omp10; Omp25; Omp2b; Omp1; rough lipopolysaccharide (R-LPS)
• Preparation: Monoclonal antibodies against individual or combinations of OMPs and rough lipopolysaccharide (R-LPS) were used for passive immunization; a mouse serum raised against B. ovis hot-saline extract containing antibodies to both OMPs and R-LPS was used as a positive control. (Bowden et al, 2000)
• Description: The study aimed to identify protective outer membrane proteins (OMPs) of Brucella ovis as vaccine candidates by testing monoclonal antibodies (mAbs) against these antigens for protection in mice. Efficacy: Monoclonal antibodies to Omp16, Omp19, and Omp31 provided significant protection against B. ovis challenge, reducing spleen infection and preventing splenomegaly; mAbs to Omp31 maintained protection even in mixtures with nonprotective mAbs. Immune response: Protective immunity was mediated by antibodies targeting surface-exposed epitopes of OMPs and R-LPS, confirming the protective role of these antigens and identifying Omp31 as a promising subunit vaccine candidate against ram epididymitis. (Bowden et al, 2000)

Mouse Response

• Immune Response: Protective immunity was mediated by antibodies targeting surface-exposed epitopes of OMPs and R-LPS, confirming the protective role of these antigens and identifying Omp31 as a promising subunit vaccine candidate against ram epididymitis. (Bowden et al, 2000)
• Challenge Protocol: Passive immunization of mice with monoclonal antibodies followed by challenge with Brucella ovis; protection was assessed by reduction in spleen infection and prevention of splenomegaly. (Bowden et al, 2000)
• Efficacy: Monoclonal antibodies to Omp16, Omp19, and Omp31 provided significant protection against B. ovis challenge, reducing spleen infection and preventing splenomegaly; mAbs to Omp31 maintained protection even in mixtures with nonprotective mAbs. (Bowden et al, 2000)
• Description: Passive immunization of mice with monoclonal antibodies followed by challenge with Brucella ovis; protection was assessed by reduction in spleen infection and prevention of splenomegaly. (Bowden et al, 2000)